These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Care of the HIV-positive patient in the emergency department in the era of highly active antiretroviral therapy. Venkat A; Piontkowsky DM; Cooney RR; Srivastava AK; Suares GA; Heidelberger CP Ann Emerg Med; 2008 Sep; 52(3):274-85. PubMed ID: 18358567 [TBL] [Abstract][Full Text] [Related]
23. Treatment of facial lipoatrophy in HIV-infected patients. Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497 [TBL] [Abstract][Full Text] [Related]
25. Human immunodeficiency virus and atherosclerosis. Farrugia PM; Lucariello R; Coppola JT Cardiol Rev; 2009; 17(5):211-5. PubMed ID: 19690471 [TBL] [Abstract][Full Text] [Related]
26. A dramatic change in HIV treatment. Wilkins K; Maurer T; Berger T J Drugs Dermatol; 2004; 3(4):452-5. PubMed ID: 15303794 [No Abstract] [Full Text] [Related]
27. Managing HIV/AIDS patients. Paul SM; Sensakovic J; Podhurst LS; Morgan DH; Triano-Davis W N J Med; 1998 May; 95(5):55-60. PubMed ID: 16013158 [No Abstract] [Full Text] [Related]
28. Hepatitis virus coinfection in the Strategic Management of Antiretroviral Therapy (SMART) study: a marker for nonliver, non-opportunistic disease mortality. Wyles DL Clin Infect Dis; 2008 Dec; 47(11):1476-8. PubMed ID: 18959495 [No Abstract] [Full Text] [Related]
29. Predicting and monitoring antiretroviral adherence. Gross R LDI Issue Brief; 2007; 13(2):1-4. PubMed ID: 18354853 [TBL] [Abstract][Full Text] [Related]
30. The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells. Sternfeld T; Schmid M; Tischleder A; Mudra S; Schlamp A; Kost BP; Gruber R; Youle M; Bogner JR; Goebel FD Antivir Ther; 2007; 12(5):769-78. PubMed ID: 17713160 [TBL] [Abstract][Full Text] [Related]
31. Adverse interactions with antiretroviral agents: focus on recreational and addiction drugs. Vassilev ZP; Marcus SM AIDS Read; 2004 Feb; 14(2):96. PubMed ID: 15083804 [No Abstract] [Full Text] [Related]
32. Structured interruptions of therapy: looking for the best protocol. Aiuti F; Giovannetti A AIDS; 2003 Oct; 17(15):2257-8. PubMed ID: 14523284 [No Abstract] [Full Text] [Related]
33. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Neuman MG; Monteiro M; Rehm J Subst Use Misuse; 2006; 41(10-12):1395-463. PubMed ID: 17002989 [TBL] [Abstract][Full Text] [Related]
34. Biomedical methods for HIV prevention: new setbacks. Laurence J AIDS Read; 2008 Apr; 18(4):163-4. PubMed ID: 18472438 [No Abstract] [Full Text] [Related]
35. [HIV antiretroviral agents: new threats to accessibility in developing countries]. Nau JY Rev Med Suisse; 2005 Dec; 1(45):2956. PubMed ID: 16425957 [No Abstract] [Full Text] [Related]
36. Stopping antiretroviral therapy: role for therapeutic drug monitoring. Tommasi C; Nicastri E; Corpolongo A; Ivanovic J; Notari S; Ascenzi P; Andreoni M; Narciso P AIDS; 2008 Jan; 22(2):315-6. PubMed ID: 18097237 [No Abstract] [Full Text] [Related]
38. Regression of a cervical spinal mass following highly active antiretroviral therapy (HAART) in child with advanced human immunodeficiency virus (HIV) disease. Leng LK; Pancharoen C; Bunupuradah T; Thisyakorn U; Trinavarat P; Sosothikul D; Ananworanich J J Med Assoc Thai; 2007 Sep; 90(9):1937-42. PubMed ID: 17957942 [TBL] [Abstract][Full Text] [Related]
39. Persistent differences in the antiviral effects of highly active antiretroviral therapy in the blood and male genital tract. Pasquier CJ; Moinard N; Sauné K; Souyris C; Lavit M; Daudin M; Izopet J; Bujan L AIDS; 2008 Sep; 22(14):1894-6. PubMed ID: 18753873 [No Abstract] [Full Text] [Related]
40. [Metabolic alterations, AIDS and vascular disease]. Betancor León P An Med Interna; 2007 Apr; 24(4):157-9. PubMed ID: 17867897 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]